Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
- PARIS & DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI)(1) inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its proprietary RADR® AI platform to uncover bi.
- 05/06/2024
|
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
- DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2024 financial results webcast on Thursday, May 9, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the.
- 05/02/2024
|
3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire
- Keep an eye on machine learning stocks. Companies are tripping over each other for the technology, which involves feeding data to a machine so it can learn and even make human-like decisions.
- 05/01/2024
|
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
- DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that – the company has launched Webinar Wednesdays, a webinar series that focuses on areas of high oncology drug development interest with leading physicians, scientists and Lantern collaborators in drug developm.
- 04/24/2024
|
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
- Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population. Dr. Yashushi Goto a leading lung cancer clinician-scientist at the renowned National Cancer Center of Japan will be a lead investigator. DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing … The post Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lu...
- 04/22/2024
|
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
- DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that – the company has received regulatory approval to expand its Harmonic™ trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan. Appro.
- 04/22/2024
|
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
- Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
- 03/18/2024
|
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
- DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2023. “This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for o.
- 03/18/2024
|
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
- DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced the dosing of the first two patients in the Phase 1 clinical trial evaluating Lantern's investigational new drug LP-284 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), including mantle cell ly.
- 03/15/2024
|
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
- DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2023 financial results webcast on Monday, March 18, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial.
- 03/11/2024
|
Lantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
- DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW. The conference will be on Thursday, March 7th, and is a virtual event. Lantern Pharma's CEO, Mr. Panna Sharma, will be discussing and presenting via a fireside chat format at The 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference at approximately 2 pm E.
- 03/05/2024
|
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
- DALLAS--(BUSINESS WIRE)--Press release about Lantern Pharma's ADC program focused on cryptophycin drug-payload ADC being developed in collaboration with Bielefeld.
- 02/15/2024
|
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
- DALLAS--(BUSINESS WIRE)--Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D. has joined Starlight as its Chief Medical Officer. Dr. Chamberlain will oversee Starlight's clinical operations, which currently include planned clinical trials for glioblastoma and other high-grade gliomas,.
- 01/17/2024
|
The 3 Most Undervalued AI Penny Stocks to Buy in December
- It's easy to understand why investors remain curious about AI penny stocks in December and beyond. Leading companies in the artificial intelligence (AI) industry have multiplied in value in 2023.
- 12/13/2023
|
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
- DALLAS--(BUSINESS WIRE)--FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL). This is the second ODD for LP-284.
- 11/30/2023
|
Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Call Transcript
- Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to our Third Quarter 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode.
- 11/09/2023
|
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
- DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights.
- 11/08/2023
|
The 7 Most Undervalued AI Penny Stocks to Buy: October 2023
- Dive into the dynamic realm of undervalued AI penny stocks, offering robust long-term upside potential. By 2030, artificial intelligence (AI) is set to fuel the global economy with a staggering $15.7 trillion injection.
- 10/24/2023
|
Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
- DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced that Lantern management will be presenting at the ThinkEquity Conference on Thursday, October 19, 2023, at the Mandarin Oriental in New York, NY. Lantern Pharma is scheduled to present at the conference at 1:30 p.m.
- 10/10/2023
|
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
- DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced the dosing of the first patient in the Phase 1 clinical trial evaluating Lantern's investigational new drug LP-184 in patients with advanced solid tumors. "The first patient dosing in our Phase 1 trial of LP-184 is.
- 09/25/2023
|
The 3 Most Undervalued Machine Learning Stocks to Buy in September 2023
- If you're wondering if there is still time to invest in machine learning stocks, some recent research will provide some useful context. A recent study by WallStreetZen revealed what many investors already suspected.
- 09/14/2023
|
3 AI Stocks That Still Trade Under $10 Per Share
- The artificial intelligence ( AI ) boom is far from over. For example let's look at Nvidia (NASDAQ: NVDA ), where CEO Jensen Huang still believes his stock is wildly undervalued.
- 08/28/2023
|
The 3 Most Undervalued Machine Learning Stocks to Buy Now: August 2023
- Despite the pullback in the technology indices and that of the broader market, the transition to artificial intelligence ( AI ) has only just begun. ChatGPT kicked off this sudden surge of interest in machine learning stocks, and it looks to have a transformational impact on society.
- 08/23/2023
|
The 3 Most Undervalued AI Penny Stocks to Buy Now: August 2023
- If you've been on the sidelines with artificial intelligence stocks, the recent pullbacks are handing investors another opportunity to buy. That includes the likes of Nvidia (NASDAQ: NVDA ), Microsoft (NASDAQ: MSFT ), Advanced Micro Devices (NASDAQ: AMD ), Palantir (NYSE: PLTR ) and dozens more, even in AI penny stocks.
- 08/16/2023
|
Lantern Pharma Inc. (LTRN) Q2 2023 Earnings Call Transcript
- Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Margave – Chief Financial Officer Conference Call Participants Nicole Leber Good afternoon, everyone. I'm Nicole Leber with Investor Relations here at Lantern Pharma.
- 08/09/2023
|
3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True
- As we forge ahead into the AI era, the top AI penny stocks have become increasingly relevant, emerging as a buzzword among savvy investors. Projected to inject a massive $15.7 trillion into the global economy by the conclusion of the current decade, AI is no longer just the playground for large-cap tech giants.
- 08/09/2023
|
3 AI Stocks You'll Regret Not Buying Soon
- Artificial intelligence ( AI ) will have a profound impact on the medical industry, where it could help accelerate drug discovery and patient treatment, creating big opportunities for these top AI stocks to invest in. At the moment, new drug development has a ridiculous fail rate of 90%, according to the National Institutes of Health.
- 08/08/2023
|
7 AI Stocks to Buy Under $5 in August 2023
- Let's take a look at some of the top AI stocks in August 2023. For the most part, the average investor is familiar with the major names in the sector, such as Nvidia (NASDAQ: NVDA ) and Microsoft (NASDAQ: MSFT ).
- 08/02/2023
|
3 AI Stocks to Buy Under $10 in August 2023
- The bull market in artificial intelligence is just getting started. In fact, with the boom only set to accelerate, we may be looking at a $1.81 trillion opportunity by 2030, says Grand View Research.
- 08/01/2023
|
7 AI Penny Stocks that Could Hit $5 Soon
- The era of artificial intelligence is upon us. By 2030, AI is expected to contribute $15.7 trillion to the global economy.
- 07/30/2023
|
3 Penny Stocks to Buy as the AI Sector Transforms Every Industry in 2023
- AI penny stocks offer investors a thrilling opportunity to tap into the fast-evolving artificial intelligence space. AI penny stocks have limited financial resources and modest profits, but their long-term growth prospects are enticing.
- 05/19/2023
|
Lantern Pharma Inc. (LTRN) Q1 2023 Earnings Call Transcript
- Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Officer and Secretary Conference Call Participants Michael King - EF Hutton Nicole Leber Good afternoon, everyone. I'm Nicole Weber with Investor Relations here at Lantern Pharma.
- 05/13/2023
|
Lantern Pharma Inc. (LTRN) Q4 2022 Earnings Call Transcript
- Lantern Pharma Inc. (NASDAQ:LTRN ) Q4 2022 Results Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Officer and Secretary Kishor Bhatia - Chief Scientific Officer Conference Call Participants John Vandermosten - Zacks Research Michael King - EF Hutton Nicole Leber Welcome to our fourth quarter and full-year 2022 earnings call. I will be your host for today's call.
- 03/20/2023
|
LTRN Stock: 7.74% Increase After Hours Explanation
- The stock price of Lantern Pharma Inc (NASDAQ: LTRN) increased by 7.74% after hours in the most recent trading session. This is why.
- 03/20/2023
|
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
- DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company will present at the American Association for Cancer Research (AACR) Annual Meeting.
- 03/15/2023
|
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
- DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its fourth quarter and fiscal year 2022 financial results webcast on Monday, March 20, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.
- 03/13/2023
|
Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last week
- Lantern Pharma Inc. LTRN, -13.13% confirmed Monday that it, or any of its subsidiaries, had no exposure to SIVB Financial Group's SIVB, -60.41% Silicon Valley Bank, Silvergate Capital Corp. SI, -11.27% or Signature Bank SBNY, -22.87% . The biopharmaceutical company's statement comes after Lantern's stock plunged 22.4% last week, the second-worst weekly performance since it went public in June 2020, to close Friday at a four-month low.
- 03/13/2023
|
7 AI Penny Stocks That Could Skyrocket in 2023
- AI penny stocks provide investors with higher-risk, higher-upside exposure to companies specializing in developing or utilizing artificial intelligence technology. Since these stocks trade at a relatively low price per share and may be relatively unproven, operating in niche areas of the market, there's more to be gained by a correct bet on these stocks.
- 02/21/2023
|
ProPhase Labs Discloses 8.4% Position in LTRN / Lantern Pharma After Q3 Results
- Fintel reports that ProPhase Labs, Inc. has filed a 13G form with the SEC disclosing ownership of 910,000 shares of Lantern Pharma Inc. (LTRN). This represents 8.4% of the company.
- 11/22/2022
|
Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET
- DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.
- 10/21/2022
|
Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET
- DALLAS, TX / ACCESSWIRE / October 11, 2022 / Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.
- 10/11/2022
|
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting
- DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present preclinical data on the potency of Lantern's drug candidate LP-284 for mantle cell lymphoma (MCL) and several other non-Hodgkin's lymphomas at the Society of Hematologic On
- 09/23/2022
|
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer
- DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present positive preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research (AACR) Special Conferen
- 09/14/2022
|
Lantern Pharma Inc.'s (LTRN) CEO Panna Sharma on Q2 2022 Results - Earnings Call Transcript
- Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Margrave – Chief Financial Officer Conference Call Participants Operator Good afternoon, everyone. I'm Nicole Leber with Investor Relations here at Lantern Pharma.
- 08/08/2022
|
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q1 2022 Results - Earnings Call Transcript
- Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate, Finance & Administrative Coordinator Panna Sharma - President & Chief Executive Officer David Margrave - Chief Financial Officer & Secretary Kishor Bhatia - Chief Scientific Officer & Scientific Consultant Conference Call Participants Nicole Leber Good evening, everybody. I am Nicole Leber with Investor Relations here at Lantern Pharma.
- 05/03/2022
|
Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET
- DALLAS, April 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, after the financial markets close.
- 04/22/2022
|
Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting
- LP-184 demonstrated anti-tumor activity in brain metastases cell models from lung, skin, and breast cancers. Brain metastases in the U.S. can occur in 10-30% of all cancer cases and are diagnosed in over 100,000 patients each year.
- 03/14/2022
|
Lantern Pharma Inc.'s (LTRN) CEO Panna Sharma on Q4 2021 Results - Earnings Call Transcript
- Lantern Pharma Inc.'s (LTRN) CEO Panna Sharma on Q4 2021 Results - Earnings Call Transcript
- 03/10/2022
|
Lantern Pharma's LP-184 Receives Rare Pediatric, Orphan Drug Tags For Rare Form Of Cancer
- The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for Atypical Teratoid Rhabdoid Tumor (ATRT), a form of cancer of the Central Nervous System. LP-184 is a small molecule drug candidate and next-generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or harbor mutations in DNA repair pathways.
- 01/24/2022
|
Lantern Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference
- DALLAS, Jan. 4, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Panna Sharma, Chief Executive Officer and President of Lantern Pharma, will be presenting at the H.C.
- 01/04/2022
|
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q3 2021 Results - Earnings Call Transcript
- Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q3 2021 Results - Earnings Call Transcript
- 11/01/2021
|
Lantern Pharma to Host Third Quarter 2021 Operating & Financial Results Conference Call on Monday, November 1, 2021 at 4:30 p.m. ET
- DALLAS, Oct. 25, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today that it will host a conference call on Monday, November 1, 2021 at 4:30 p.m.
- 10/25/2021
|
Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
- DALLAS, TX / ACCESSWIRE / September 30, 2021 / Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company has been invited to present at the Fall Harvest - Best Ideas from the Buy-Side conference, which is being held virtually on October 5 - 8, 2021.
- 09/30/2021
|
Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer
- DALLAS and COLUMBUS, Ohio, Sept. 28, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.
- 09/28/2021
|
Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September
- DALLAS, Sept. 7, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.
- 09/07/2021
|
Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives
- DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.
- 09/02/2021
|
Lantern Pharma's LP-184 Receives Orphan Drug Tag For Brain Cancer Indication
- The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for glioblastoma multiforme (GBM) and other malignant gliomas. The news follows the recent announcement of the FDA granting LP-184 Orphan Drug tag for pancreatic cancer.
- 08/30/2021
|
Preclinical Data Of Brain Tumor Candidate Fails To Lift Lantern Pharma Stock
- Lantern Pharma Inc (NASDAQ: LTRN) announced preclinical data of its drug candidate LP-184, showing its potential to inhibit tumor growth and improve survival in animals models of glioblastoma (GBM). LP-184 treatment induced tumor regression evidenced by greater than 106% tumor growth inhibition in two subcutaneous xenograft models of GBM (U87 and M1123).
- 08/19/2021
|
Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration
- DALLAS and BALTIMORE, Aug. 19, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company, announced today that a successful preclinical study has shown its drug candidate LP-184 is able to inhibit tumor growth and improve survival in animal models of glioblastoma (GBM). This study was conducted in collaboration with the research group of John Laterra, M.D.
- 08/19/2021
|
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer
- DALLAS, Aug. 16, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract titled 'LP-184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects' has been accepted as a virtual poster at the upcoming AACR Virtual Special Conference on Pancreatic Cancer being held on September 29-30, 2021.
- 08/16/2021
|
Lantern Pharma Secures FDA Orphan Drug Tag For Pancreatic Cancer Candidate
- The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for pancreatic cancer. LP-184 is a small molecule drug candidate and next-generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or harbor mutations in DNA repair pathways.
- 08/11/2021
|
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
- DALLAS, Aug. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-184 Orphan Drug Designation for the treatment of pancreatic cancer.
- 08/11/2021
|
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q2 2021 Results - Earnings Call Transcript
- Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q2 2021 Results - Earnings Call Transcript
- 07/31/2021
|
Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S
- DALLAS, July 27, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for Irofulven (LP-100) from Allarity, formerly known as Oncology Venture.
- 07/27/2021
|
Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven
|
Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET
- DALLAS, July 22, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Thursday, July 29, 2021 at 4:30 p.m.
- 07/22/2021
|
LTRN Stock Increases Over 10% Pre-Market: Why It Happened
- The stock price of Lantern Pharma Inc. (NASDAQ: LTRN) increased by over 10% pre-market. This is why it happened.
- 07/20/2021
|
Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models
- Lantern Pharma Inc (NASDAQ: LTRN) has announced new preclinical data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center. These data demonstrated that the drug candidate, LP-184, exhibited significant and rapid pancreatic tumor shrinkage, by over 90%, in in-vivo mouse models in 8 weeks.
- 07/20/2021
|
Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
- DALLAS, July 20, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today positive new data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center.
- 07/20/2021
|
3 Little Known AI Stocks for the Future
- With the global release of 5G connectivity, machine learning has become more of a secular trend than ever before.
- 07/18/2021
|
Lantern Pharma: Drug Recycling With AI
- Lantern Pharma: Drug Recycling With AI
- 06/08/2021
|
Lantern Pharma - Using AI to Transform The Cost & Risk of Cancer Drug Development
- Artificial intelligence is one of the most fascinating and powerful technological advances to come along over the past decade. The idea that we can use machine learning and data to make a positive impact in all different types of industries is certainly attractive from an investing perspective.
- 05/25/2021
|
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q1 2021 Results - Earnings Call Transcript
- Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q1 2021 Results - Earnings Call Transcript
- 05/04/2021
|
Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights
- DALLAS, May 3, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced financial results for the first quarter ended March 31, 2021.
- 05/03/2021
|
Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform
- DALLAS, May 3, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today that it has entered into a research and development collaboration with Actuate Therapeutics.
- 05/03/2021
|
Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company's Progress in the Development of Biopharma Collaborations and Partnerships and Advancing the Company's Strategy to Develop the World's Largest A.I.
- DALLAS, April 29, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that RADR® has exceeded 4.6 billion datapoints.
- 04/29/2021
|
Lantern Pharma to Host First Quarter 2021 Operating and Financial Results Conference Call on May 3, 2021 at 4:30 p.m. ET
- DALLAS, April 26, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Monday, May 3, 2021 at 4:30 p.m.
- 04/26/2021
|
Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget
- DALLAS, April 26, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, announced a manuscript describing the efficacy profile of LP-184 in a variety of non-small cell lung cancer models was published in Oncotarget.
- 04/26/2021
|
Lantern: Changing The Cost-Curve, Changing The Risk, AI-Biotech Unlocks New Value
- Lantern Pharma Inc. is a clinical-stage oncology biotechnology company utilizing AI, machine learning, and genomic data to develop, streamline, rescue, and revitalize small-molecule drugs (oftentimes abandoned or failed) for targeted oncology patients.
- 04/09/2021
|
Lantern Pharma to Participate in the Virtual 20th Annual Needham Healthcare Conference
- DALLAS, April 6, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced that Panna Sharma, President and CEO of Lantern Pharma, will participate in the 20th Annual Needham Healthcare Conference, to be held virtually on April 12-15, 2021.
- 04/06/2021
|
Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021
- DALLAS, March 23, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, will present new data on LP-184, a next-generation, targeted small molecule in the acylfulvene drug class, showcasing its potency across various 2D and 3D models of prostate cancer, at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place from April 10-15, 2021.
- 03/23/2021
|
Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties
- DALLAS, March 17, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced that it has filed seven patent applications globally on a novel DNA-damaging agent with anticancer properties.
- 03/17/2021
|
Lantern Pharma Interview to Air on Bloomberg TV in the US on the RedChip Money Report®
- DALLAS, March 12, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, today announced that an interview with CEO Panna Sharma will air on The RedChip Money Report® on Bloomberg TV in the US on Saturday, March 13, at 7 p.m.
- 03/12/2021
|
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q4 2020 Results - Earnings Call Transcript
- Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q4 2020 Results - Earnings Call Transcript
- 03/10/2021
|
Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights
- DALLAS, March 10, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced financial results for the fourth quarter and fiscal year ended December 31, 2020.
- 03/10/2021
|
Predictive Oncology: Potentially Undervalued Drug Discovery AI Company
- Predictive Oncology: Potentially Undervalued Drug Discovery AI Company
- 02/24/2021
|
Lantern Pharma Announces Pricing of $60 Million Public Offering
- DALLAS, Jan. 14, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology...
- 01/14/2021
|
Lantern Pharma (LTRN) Investor Presentation - Slideshow
- The following slide deck was published by Lantern Pharma Inc. in conjunction with this event..
- 09/04/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 08/30/2020
|
Stocks To Watch: Nvidia, Intel And Zoom Look To Dazzle
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 08/29/2020
|
Big Data Analytics Market 2020 Global Significant Growth,Technological Advancement & Opportunities To 2025
- WiseGuyReports.com Publish A New Market Research Report on –“ Big Data Analytics Market 2020 Global Significant Growth,Technological Advancement &
- 08/21/2020
|
AI Is Booming: Here Are 3 Stocks Analysts Are Betting On
- Artificial Intelligence isn’t just science fiction anymore. The technology is maturing, and AI is allowing machines to take an ever-growing role is more and more sectors of our digital world. Financial services, healthcare, manufacturing, and retail all are being transformed – to varying degrees, and as varying paces – by AI applications.In retail, AI tech is transforming inventory systems, making it easier for employees to track stock from the backrooms to the shelves. Office environments are changing, too, as AI has smoothed over the transition to mass work-from-home by easing IT support systems. Perhaps the greatest changes are coming in field of language processing, where natural language AI is producing chatbots that sound more and more like human beings. Machine learning is making it possible for the machines to answer questions posed by humans.It’s no wonder, then, that stocks involved in developing, using, and marketing AI technology are – in many cases – showing gains. Using TipRanks database, we pinpointed three that fit the bill. They’re an interesting lot, spread across a variety of sectors, each with their own approach to artificial intelligence.Lantern Pharma (LTRN)We will start with Lantern Pharma, a biotech firm involved in cancer treatment. Lantern is working with AI and machine learning platforms to leverage the highest possible gains from its database of patient information. The company aims to assemble a base of 1 billion data points for analysis in new drug development; a database that size requires the more flexible architecture of AI analysis to find sense in its sheer volume.The reward potential is high, however, as success will allow Lantern to develop more effective cancer treatments on a faster timeline. The company is currently using AI, machine learning, and cloud computing simultaneously with genomic data in an effort to target its research on the most receptive patient populations. The short-term goal is to de-risk and streamline clinical trials, with a long-term goal of identifying the patients most likely to respond to a particular treatment.Like most cutting-edge biotech firms, Lantern operates with a net loss. The most recent quarter saw negative EPS of 31 cents, in line with the year-ago quarter’s 32 cents. The stock has been trading publicly since June, and in that time has fallen 25%.ThinkEquity analyst Ashok Kumar is impressed enough by LTRN to initiate coverage of the stock with a Buy rating and a $25 price target. His target implies an impressive upside potential of 127%. (To watch Kumar’s track record, click here)Backing his view, Kumar writes, “Together with the rapid advances in big data and AI applications, improved preclinical models will help to accelerate the process of novel drug discovery and refine therapeutic choices, thereby addressing a growing unmet medical need. Lantern RADR Machine Learning Platform, developed using Artificial Neural Network as the primary predictive algorithm, is uniquely positioned to monetize this opportunity.”It has been relatively quiet when it comes to other analyst activity. Overall, in the last three months, only 2 analysts have issued ratings. However, as they were both Buys, the word on the Street is that LTRN is a Moderate Buy. Based on the $24.50 average price target, shares could climb nearly 120% higher in the next twelve months. (See LTRN stock analysis on TipRanks)LivePerson, Inc. (LPSN)And now we move on to the customer service sector, where LivePerson has long been an innovator in direct customer contact and person-to-person chat. The company’s chat platforms are used in customer service applications, and are available through mobile devices, social media, and traditional web browsers. LivePerson has, for the last two years, offered a conversational AI to clients, allowing automated chatbots to handle basic communications with help center customers.LivePerson’s AI chatbots are based on the Conversational Cloud, an application that allows a human agent to oversee multiple AI bots. The system is designed to maximize contact center efficiency, with the AI handling initial contacts and basic filtering questions and the human overseers picking up the more complex issues. LivePerson’s clients – the companies using the chat platforms and chatbots – have options to use ready-made AI systems, or to use LivePerson’s platform to create unique automated conversations.LivePerson saw $291.6 million in revenue for 2019, a 17% year-over-year gain. The revenue gains continued into 1H20, with the most recent quarter showing a forecast-beating $91.6 million. This was up 28% year-over-year. Despite the strong revenues, LPSN operated a net loss in the quarter, although the loss was sequentially smaller than in the first quarter. The stock has strongly outperformed the overall markets in recent months, almost tripling in share price since hitting bottom on March 18.5-star analyst Michael Latimore, of Northland Securities, is impressed by LivePerson’s growth in recent months. He writes of the stock, “In addition to accelerated demand, a price increase on automated interactions could provide a major rev uplift. LPSN has a unique opportunity to provide the conversational commerce platform, leveraging large amounts of proprietary conversational data. Other leading SaaS and CSaaS companies, such as EVBG, FIVN, RNG, and TWLO, trade well into the double digit revenue multiples." The analyst added, "The opportunity is large and LPSN is now showing metrics in-line with other leading CSaaS companies, such as 29% revenue growth and 10% EBITDA margins in 2Q. Raising target to $70 from $45 based on about 11x FY21 revenue."To this end, Latimore rates LPSN an Outperform (i.e. Buy) and his $70 price target suggests room for another 17% growth in the next year. (To watch Latimore’s track record, click here)LivePerson shares are currently selling for $60.98. The stock’s average price target is $63.60; recent gains have pushed the share price close to the target, leaving a modest 4% upside potential. (See LivePerson stock analysis on TipRanks)Booz Allen Hamilton Holding (BAH)Last on our list is a Beltway Bandit, one of the plethora of consulting firms that inhabit the suburbs of Washington, DC and make their living offering services to the Federal Government. Booz Allen Hamilton specializes in management and information technology, with most of its clients in the government markets: the defense department, the intelligence services, and the civil administration. BAH has been working to combine data science with AI for the past several years, developing systems to make Big Data work effectively and efficiently for its government contract clients. The company has set up an AI-driven process automation system for the Veterans Administration, used to speed up veterans’ benefits and claims compensations. Last year, BAH launched a scalable AI platform, Modzy, to make machine learning systems more accessible for clients. And more recently, this year, the company has been working with Federal clients to apply AI systems to the general coronavirus response.Government contracting is a lucrative niche, and being able to offer top-notch technology only helps a company’s position. BAH, in the past quarter, saw earnings grow 27% sequentially, on $1.96 billion in top line revenues. Covering the stock for William Blair, analyst Louie DiPalma opined: “Booz Allen has established itself as the leading provider of government artificial intelligence services [...] Booz Allen's internally developed Modzy platform has proved to be a tremendous success thus far, and it is still in its very early innings.”DiPalma’s upbeat comments come with an Outperform (i.e. Buy) rating on the stock. (To watch DiPalma’s track record, click here)To find good ideas for AI stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- 08/18/2020
|
Lantern Pharma Interview to Air on Bloomberg International on the RedChip Money Report
- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, today announced that an interview with its CEO and President Panna Sharma will air on The RedChip Money Report television program. The interview will air Sunday, August 16, 2020 at 6 p.m. local time on Bloomberg International, available in 100+ million homes across Europe.
- 08/14/2020
|
LD Micro - Announces Preliminary List of Presenters for the LD 500
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
Insights on the Culinary Tourism Global Market to 2027 - Opportunity Analysis and Industry Forecast - ResearchAndMarkets.com
|
Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress
- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, today announced its financial results for the second quarter ended June 30, 2020, and provided an update on its R&D pipeline and other corporate developments.
- 07/30/2020
|
Earnings Scheduled For July 30, 2020
- Companies Reporting Before The Bell
• Mastercard Inc. (NYSE:MA) is expected to report quarterly earnings at $1.16 per share on revenue of $3.23 billion.
• Moody's...
- 07/30/2020
|
Stocks To Watch: Big Focus On Big Tech
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 07/25/2020
|
Lantern Pharma to Host Second Quarter 2020 Operating and Financial Results Conference Call on July 30, 2020
- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development and, identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Thursday, July 30, 2020 at 8:00 a.m. Eastern Time to discuss financial and operating results for the second quarter ended June 30, 2020.
- 07/24/2020
|
Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Glioblastoma
- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence ("A.I."), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced entering into agreements with leading contract manufacturing companies for process development and manufacturing for two of Lantern's oncology drug candidates, LP-300 and LP-184. Lantern Pharma filed an 8-K on Thursday, July 16 describing a recent agreement for GMP manufacturing.
- 07/20/2020
|
'Zooming with LD' to Feature 10 Distinct Companies July 20th-31st
- LOS ANGELES, CA / ACCESSWIRE / July 16, 2020 / LD Micro today announced that it will be hosting ten companies over the final two weeks of July, with a group presentation in the morning, followed by private ...
- 07/16/2020
|
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Data Points Curated Specifically for Oncology Drug Development and Drug Response Prediction
- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and Rescue). RADR® leverages genomic, transcriptomic, clinical and drug sensitivity data points across more than 145 drug-tumor interactions to predict the potential response cancer patients will have to potential drugs, therefore enabling a more personalized approach to therapy that is aimed at better outcomes.
- 06/29/2020
|
Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting
- Lantern Pharma (LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it will make two presentations at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting, a meeting of global leaders in cancer research taking place from June 22-24, 2020. Each presentation will examine Lantern Pharma’s use of its A.I. platform, RADR® (Response Algorithm for Drug Positioning and Rescue), in the development of LP-184, one of three cancer drugs in Lantern Pharma’s pipeline.
- 06/17/2020
|
Lantern Pharma Announces Closing of Initial Public Offering
- Lantern Pharma Inc. (LTRN) (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, today announced the closing of its initial public offering of 1,750,000 shares of its common stock at a public offering price of $15.00 per share, for gross proceeds of $26,250,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 262,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments.
- 06/15/2020
|
The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) * AbbVie Inc (NYSE: ABBV) - announced an oncology partnership with GENMAB A/S/S ADR (NASDAQ: GMAB) * Adverum Biotechnologies Inc (NASDAQ: ADVM) * CALLIDITAS THER/S ADR (NASDAQ: CALT) (went public June 5) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Cerus Corporation (NASDAQ: CERS) * ChemoCentryx Inc (NASDAQ: CCXI) * Curis, Inc. (NASDAQ: CRIS) (announced FDA nod for commencing clinical studies of a drug to treat solid tumors) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Dyadic International, Inc. (NASDAQ: DYAI) * ITAMAR MED LTD/S ADR . (NASDAQ: ITMR) * Kiniksa Pharmaceuticals Ltd . (NASDAQ: KNSA) * Neoleukin Therapeutics Inc (NASDAQ: NLTX) * Novo Nordisk A/S (NYSE: NVO) * Passage Bio Inc (NASDAQ: PASG) * Sarepta Therapeutics Inc (NASDAQ: SRPT) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * Vermillion, Inc. (NASDAQ: VRML) (shares are set to join the Russell 3000 Index)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 10) * Ayala Pharmaceuticals Inc (NASDAQ: AYLA) * Evofem Biosciences Inc (NASDAQ: EVFM)Stocks In Focus Sorrento Applies For Emergency Use Authorization For Rapid COVID-19 Diagnostic Test Kit Sorrento Therapeutics Inc (NASDAQ: SRNE) said it has submitted to the FDA an Application for Emergency Use Authorization for its COVI-TRACK in vitro diagnostic test kit for the independent detection of IgG and IgM antibodies in sera of patients exposed to the SARS-CoV-2 virus.The company said the test allows results to be available in 8 minutes or less.The stock was jumping 10.35% to $5.01 in premarket trading Thursday.Bristol-Myers' Opdivo Receives Another FDA Approval Bristol-Myers Squibb Co (NYSE: BMY) announced FDA approval for its Opdivo for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.The stock was moving down 0.93% to $59.60 in premarket trading Thursday.Grifols Starts Production of Hyperimmune Immunoglobins For Clinical Study In COVID-19 Spanish biopharma Grifols SA - ADR ADR Class B (NASDAQ: GRFS) said it has started production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. It is the first specific drug developed to combat COVID-19.The company, which is part of a collaboration agreement with entities such as the FDA, NIH and BARDA to produce potential anti-COVID-19 passive immune therapy, said the hyperimmune immunoglobins are being produced in its U.S. facility, and the first doses are expected to be available in July 2020 for clinical trials.See also: The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage Amag Announces Abrupt Departure Of CFO AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) said CFO and COO Edward Myles is leaving the company effective immediately. It named senior vice president of finance Brian Piekos as interim CFO.In premarket trading Thursday, the stock was climbing 10.91% to $9.FDA Approves Label Update For Novartis Wet Age-Related Macular Degeneration Treatment Novartis AG (NYSE: NVS) said the FDA approved a label update for its wet age-related macular degeneration treatment Beovu to include additional safety information regarding retinal vasculitis and retinal vascular occlusion.This approval follows the company's announcement that it would pursue worldwide label updates after a review and further characterization of rare post-marketing safety events reported to Novartis.View more earnings on IBBThe stock was down 0.66% at $87.42 premarket Thursday.Clovis Completes Enrollment In Pivotal Trial For Rubraca-Opdivo Combo Clovis Oncology Inc (NASDAQ: CLVS) announced the completion of target patient enrollment in the Phase 3 ATHENA trial evaluating the combination of Rubraca, and Bristol-Myers Squibb's Opdivo as front-line maintenance treatment of newly diagnosed advanced ovarian cancer.The company expects to release top-line data from the monotherapy arm in the second-half of 2021, with the results likely to support a potential BLA filing. The combo arm is likely to read out one year or more later.In premarket trading Thursday, Clovis Oncology stock was down 3.36% at $6.90.Zynex To Join S&P; SmallCap 600 Index Medical device maker Zynex Inc. (NASDAQ: ZYXI) said it will replace KEMET Corp. (NYSE: KEM) in the S&P; SmallCap 600 effective prior to the opening of trading Tuesday, June 16. KEMET has agreed to be acquired by Yageo Corp. in a deal expected to be completed on or about June 15, pending final conditions.In premarket trading Thursday, the stock was advancing 5.03% to $22.33.Offerings Mustang Bio Inc (NASDAQ: MBIO) said it is proposing to offer shares of its common stock in an underwritten public offering. All the shares are being offered by the company. It said it intends to use the net proceeds primarily for the continued development of its product candidates, the potential in‐license, acquisition, development and commercialization of other pharmaceutical products and for general corporate purposes.The stock was down 23.91% at $3.50 premarket Thursday.ChemoCentryx said it has priced an underwritten public offering of 5.2 million shares at $58 per share for generating gross proceeds of $301.6 million. The offering is expected to close on June 15.Catalent Inc (NYSE: CTLT) said it has launched an underwritten public offering of $550 million of its common stock. The company said it intends to use the net proceeds primarily to pay off debt.The stock was down 6.2% to $70 in premarket trading Thursday.On The Radar PDUFA Dates The FDA is set to rule on Viela Bio Inc's (NASDAQ: VIE) BLA for inebilizumab in treating neuromyelitis optica spectrum disorder, a rare autoimmune disorder.Earnings Advaxis, Inc. (NASDAQ: ADXS) (before the market opens)IPO Dallas, Texas-based clinical-stage biotech Lantern Pharma, which uses AI, machine language and genomic data to develop drugs and identify patients who can benefit from targeted oncology therapies, priced its upsized initial public offering of 1.75 million shares of its common stock at $15 compared to the estimated price range of $15-$17. The shares of the company have been approved for listing on the Nasdaq under the ticker symbol "LTRN."Related Link: Novavax Analyst Says DoD Funding Reflects Conviction In Platform, Ability To Deliver On Vaccine See more from Benzinga * The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/11/2020
|
